The Solubility of an active drug molecule is the quantity of a drug (solute) that can be dissolved in a particular solution (solvent) at a fixed temperature and pressure to generate a saturated solution. It is a fundamental quality that must be assessed throughout the early phases of drug research. Active drug solubility analysis is the technique of calculating the dissolution curve of a molecule in a given volume of solvent, which is useful for gaining a basic knowledge of the medicine's pharmacodynamic qualities. As a result, Solubility Analysis is critical in the creation of medication formulations. A solution is a homogenous combination of one or more solutes in a solvent. Sugar cubes in a cup of tea or coffee are a popular example of a solution. Solubility refers to the quality that allows sugar molecules to dissolve. As a result, the term solubility may be defined as the ability of a material (solute) to dissolve in a specific solvent. A solute is any material that dissolves in a solvent and might be solid, liquid, or gas. Solubility analysis is the technique of determining the dissolution profile of a chemical in a given volume of solvent. The determination of Drug Material Solubility has a substantial impact on bio/pharmaceutical development and is beneficial for a preliminary knowledge of the pharmacodynamic features.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia